[Hormonal contraception with ethinylestradiol and gestoden. The effects on glucose tolerance and lipid metabolism].

K. Petersen,S. Skouby,A. Dreisler,C. Kühl

1987-06-08

Abstract: Only a few years following the introduction of combination oral contraceptives, it was determined that these hormonal preparations led to changes in the glucose and lipid metabolisms, which must be considered as potentially harmful. For example, women with no known disposition to diabetes mellitus may acquire diabetic glucose-overloading with use of oral contraceptives. In addition, the increased occurrence of cardiovascular complications among oral contraceptive users is thought to be directly associated with the effect of lipoprotein displacement. To reduce these effects, a new triphasic combination oral contraceptive, consisting of ethinyl-estradiol and gestodene (15-levonorgestrel), has been introduced. This study specifically investigated the effects of glucose tolerance and lipid metabolism from using this new preparation. 10 women between ages 21-32 (average age 25) participated. All had normal weights and were without known disposition to diabetes mellitus or heart disease. After receiving a medical examination, the women were given the 3-phase pill for 6 months. The pills were administered cyclically according to the usual schedule for oral contraceptives. In each cycle, the dosage consisted of 0.030 mg ethinyl-estradiol (EE) and 0.050 mg gestodene from day 1-6, then 0.400 mg EE and 0.070mg GD from days 7-11, and finally 0.030 mg EE and 0.100 mg GD in the last 10 days. Laboratory tests were done in the luteal phase before the trial's start, and before the final 10 days of the trial in the 2nd and 6th cycle. Fasting levels of plasma glucose and insulin were monitored. Though there are as yet no publications which deal with the influence of gestodene on glucose tolerance, the results from the present study indicate that gestodene in this 3-phase pill does not alter glucose tolerance in women with normal health. The raised AVC value for insulin, which was observed 6 months after treatment, may however indicate that he glucose homeostasis during treatment was maintained due to raised endogenous insulin secretion. It is therefore possible that individuals with latent insulin deficiency might acquire diabetic glucose tolerance because of an inability to show adequate insulin response.